CBUS

1.2101.63%
RB

Rory Balfour Riggs

Co-Founder & Director

Mr. Rory Balfour Riggs, MBA, serves as Observer at Cristcot LLC. He served as Chief Executive Officer of Cibus, Ltd. since October 2021 until February 2025. He serves as Director of Cibus, Inc. He is Co-Founder at Cibus, Inc. and was its Chief Executive Officer since October 2021 until February 2025 and was its Chairman since June 1, 2023 until 2025. Mr. Riggs co-founded Cibus Global and served on Cibus Global’s Board of Directors since 2001 and as Chair of the Cibus Global Board since 2014. He Co-Founded Cibus, Ltd. He serves as Chief Executive Officer of Syntax Advisors, LLC. He founded Locus Analytics, LLC in 2010 and serves as its Chief Executive Officer. He served as President of Biomatrix since 1995 until 2000. Mr. Riggs is the Founder & CEO of Syntax & Locus Analytics (also known as Biomatrix) in 2010. Mr. Riggs serves as the Managing Member of Balfour, LLC. He is Founder and Executive Chairman of Syntax LLC. He is a General partner at New Ventures Funds. Since 1991, Mr. Riggs has been affiliated with ITIM Corp. and Pharmaceutical Partners LLC. He served as the President of Biomatrix, Inc. since April 1, 1996 until 2000. He served as the Chief Financial Officer of Biomatrix from September 1996 to January 2000. From 1991 to 1995, he served as the Acting President and Chief Executive Officer of RF&P Corporation. Until 1990, he served as the Managing Director in the Mergers & Acquisitions Department at PaineWebber Incorporated, where he was employed. Mr. Riggs has an extensive record of executive leadership and innovation in the healthcare and biotechnology fields. He is former Chairman and director of Royalty Pharma. He is the Chairman of the Board at Cibus, Ltd., Nucelis Inc. and eReceivables Inc. Mr. Riggs also served as an Associate at Strategic Planning Associates, the predecessor company to Mercer Management Consulting and has been involved in the start-up of many companies including: Chondrogene Limited, Cibus Genetics, Fibrogen, Inc., Royalty Pharma AG, Selectide Inc., Sugen Inc., eAppeals, LLC, Medrium, Inc., Pharmaceutical Partners and Pacific Media. He was involved in the founding or start-up of most of these companies. He has financial expertise and experience as a developer (Founder), Executive Officer and Director of successful companies (both public and private) in the life sciences and healthcare industries. He has extensive knowledge in the life sciences industry. He Co-founded RP Management, LLC (Royalty Pharma Investments) in 1996 and has been its Chairman of the Board since 2003. He was Chairman at Calyxt, Inc. since 2014 until June 1, 2023 and was its Director since 2001 until June 1, 2023. He is a co-Founder and Chairman of the Board at Nuredis Inc. He served as the Chairman of StageZero Life Sciences Ltd. (formerly known as GeneNews Limited) from February 4, 2002 to July 2013 and has been its Independent Director since 2000. In addition, he has co-founded and served on the board of several important biotechnology companies including Sugen and Fibrogen. He had been Director of Royalty Pharma plc since June 7, 2020 until June 6, 2024. He served as Director at Intra-Cellular Therapies, Inc. since January 8, 2014 until April 02, 2025. He had been a Director of FibroGen, Inc since October 1993 until June 16, 2022. Since June 2006, Mr. Riggs has also serves as a managing Member of New Ventures, a series of venture funds focused on biotechnology. He serves as a Member of the Advisory Board at Celtic Pharma Management L.P. He served as a Director of Biomatrix, Inc. since October 1990 and also served as President since April 01, 1996, until its sale to Sanofi/Genzyme. During his tenure, he led the development and global commercial launch of an important new category for the treatment of osteoarthritis: viscosupplementation; and the leading product in the category: Synvisc®. He is a Director of Stage Zero Life Sciences (OTCMKTS: SZLSF) and a co-founder and Partner of Scientia Ventures LLC. He served as a Director of Medrium, Inc. and Sparton Corporation. Mr. Riggs is also a pioneer in the field of Systems Economics and the inventor of a new information system called FIS® (Functional Information System) for the functional mapping of systems data in biology and economics. Mr. Riggs received a B.A. Degree from Middlebury College and an MBA Degree from the Columbia University’s Graduate School of Business.

公司職務